针对阿尔茨海默病的外体工程:从致病源到临床翻译的多目标治疗策略
Yuehan Zhang1,2, Zhenyang Li2, Haien Guan1
1Center of Stem Cell and Regenerative Medicine, The People's Hospital of Gaozhou, Guangdong, China.
Clinical and translational medicine
|December 16, 2025
概括
工程外体提供了一个有前途的阿尔茨海默病 (AD) 治疗,通过穿越血脑屏障 (BBB) 进行向药物输送. 修改使得多目标策略能够对抗AD病理,并推进临床转化.
科学领域:
- 神经科学是一个神经科学.
- 生物技术是生物技术.
- 纳米医学是一种纳米医学.
背景情况:
- 阿尔茨海默病 (AD) 的发病过程复杂,血脑屏障 (BBB) 限制了传统的治疗方法.
- 工程外体,自然的纳米级囊泡,由于生物相容性,低免疫性和BBB透性,显示了AD治疗的潜力.
研究的目的:
- 为AD治疗提供工程外体特征和修改的系统概述.
- 突出工程外体在调节关键AD病理途径方面的潜力.
- 概述一个路线图,以临床翻译的工程外体基AD治疗.
主要方法:
- 对合成和结构外体细胞特征的审查.
- 专注于功能化的物理,化学和遗传修改.
- 对外体应用在准粉样β,,神经炎症和突触功能障碍方面的研究.
主要成果:
- 工程外体可以通过针对大脑的胺进行修改,以实现精确的输送.
- 它们通过共同交付药物来促进多目标治疗策略和协同效应.
- 工程外体可以调节AD核心病理,如粉样β沉积和神经炎症.
结论:
- 工程外体构造为高级阿尔茨海默病治疗提供了一个可行的平台.
- 临床翻译的挑战包括可扩展的生产和安全评估.
- 合理的设计策略对于开发下一代AD疗法至关重要.
相关概念视频
Overview of Exosomes
3.4K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
3.4K
Alzheimer's Disease: Treatment
752
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
752
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K


